Evidence map›Paper›PMID 38932450›Full record

ArticleCancer science2024

Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.

Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Youyou ShaoDepartment of Nephrology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jingying ZhangDepartment of Thyroid Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhi FengDepartment of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Wei WuDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Xiaotian ZhaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Minyi ZhuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Yao XiaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Jiaohui PangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Junfei ZhuDepartment of Respiratory and Critical Care Medicine, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Hao QuDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Minchi YuanDepartment of Oncology, The First People's Hospital of Jiashan, Jiashan, China.
Guojie XiaDepartment of Medical Oncology, Traditional Chinese Medical Hospital of Huzhou, Huzhou, China.
Meng LiuDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hengyuan LiDepartment of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-5913-1414

Funding

Medical and Health Science and Technology Plan of Department of Health of Zhejiang Province 2023RC171The Natural Science Foundation of Zhejiang Province LTGD23C040001Traditional Chinese Medical Science and Technology Plan of Zhejiang Province 2023ZR108Zhejiang Provincial Medicine and Health Research Foundation 2023KY407Zhejiang Provincial Traditional Chinese Medicine Science Research Foundation 2022ZA095
6 · The paper itself

Abstract

Atypical L858R or other L858X mutations in the epidermal growth factor receptor (EGFR) gene, beyond the classical EGFR

Indexed as

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationTyrosine Kinase InhibitorsAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeEGFR protein, humanErbB ReceptorsTyrosine Kinase InhibitorsEGFREGFR L858REGFR tyrosine kinase inhibitorfirst‐line treatmentnon‐small cell lung cancer

Identifiers

PMID38932450
PMCPMC11309923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.